問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei City Hospital Songde Branch (在職)

Division of Psychiatry

Taipei City Hospital (在職)

Division of Psychiatry

Linkou Chang Gung Medical Foundation (在職)

Division of Psychiatry

更新時間：2023-09-19

林式穀
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林式穀

List

41Cases

2021-05-31 - 2027-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2007-02-25 - 2008-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2007-02-01 - 2008-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2017-09-01 - 2019-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2014-10-09 - 2018-12-31

Phase III

Confirmatory Study of DSP-5423P in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    Schizophrenia

  • Test Drug

    DSP-5423P

Participate Sites
6Sites

Terminated6Sites

黃宗正
National Taiwan University Hospital

2011-08-01 - 2015-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Study ended5Sites

2011-11-01 - 2014-08-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2024-05-01 - 2024-05-21

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2024-05-01 - 2024-05-29

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-12-01 - 2017-12-31

Phase III

An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients with Opioid Use Disorder.

  • Condition/Disease

    opioid use disorder

  • Test Drug

    CAM2038 q1w（buprenorphine FluidCrystal&#174;每週一次長效注射劑）; CAM2038 q4w（buprenorphine FluidCrystal&#174;每月一次長效注射劑）

Participate Sites
3Sites

Terminated3Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB